EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer

Kanako Sakaeda, Koji Kurose, Yuki Matsumura, Satoshi Muto, Minoru Fukuda, Nanae Sugasaki, Masaaki Fukuda, Shinnosuke Takemoto, Hirokazu Taniguchi, Takeshi Masuda, Katsuhiko Shimizu, Yuki Kataoka und 11 weitere

Cancer Treatment and Research Communications · 2024

DOI: 10.1016/j.ctarc.2024.100830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2024. Verfasst von Kanako Sakaeda und 22 weiteren Autor:innen. Beteiligte Einrichtung: Central Research Laboratories, Sysmex Corporation, Kobe, Hyogo 651-0073, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Membrane Proteins, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: NY-ESO-1 and XAGE1 cancer/testis antigens elicit humoral and cellular immune responses in NSCLC patients. We aimed to predict clinical benefit with ICI monotherapy, using an automated immunoassay of NY-ESO-1/XAGE1 antibodies (Abs). METHODS: This study enrolled 99 NSCLC patients who received nivolumab after chemotherapy, including 21 patients harboring EGFR, ALK, or KRAS alterations. The cutoff value (10 units/mL) of NY-ESO-1 and XAGE1 Ab was determined based on Ab levels in non-malignant controls, and NY-ESO-1/XAGE1 Abs in NSCLC were measured before nivolumab. Differences in PFS and OS between the Ab-positive and Ab-negative groups were retrospectively analyzed using Cox regression analysis after applying inverse probability of treatment weighting (IPTW). RESULTS: NY-ESO-1/XAGE1 Abs were positive in 28 NSCLC, who responded more highly to nivolumab than the Ab-negatives (response rate 50.0% vs. 15.5 %, p < 0.0007). The IPTW-adjusted positives and negatives for NY-ESO-1/XAGE1 Abs were 24.5 and 70.2, respectively. The Ab-positives showed longer IPTW-adjusted PFS (HR = 0.59, 95 % CI: 0.39-0.90, p = 0.014) and IPTW-adjusted OS (HR = 0.51, 95 % CI: 0.32-0.81, p = 0.004) than the Ab-negatives. Among NSCLC harboring driver genes, the Ab-positives (n = 10) showed longer PFS (HR = 0.34, 95 % CI: 0.13-0.89, p = 0.029) and OS (HR = 0.27, 95 % CI: 0.098-0.75, p = 0.012) than the Ab-negatives (n = 11). CONCLUSION: Our immunoassay of NY-ESO-1/XAGE1 Abs is probably useful for predicting the clinical benefit with nivolumab in NSCLC, including those harboring driver genes. These results suggest that our immunoassay may be useful in ICI monotherapy for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMembrane ProteinsImmune Checkpoint InhibitorsAntigens, NeoplasmNivolumabHumansMaleFemaleAgedMiddle AgedRetrospective StudiesImmunoassayAged, 80 and overAdultBiomarkers, Tumor

Stichwörter der Autor:innen

AutoantibodyBiomarkerCancer/testis antigenImmunotherapyTertiary lymphoid structures

Substanzen

CTAG1B protein, humanMembrane ProteinsImmune Checkpoint InhibitorsAntigens, NeoplasmNivolumabXAGE1A protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Central Research Laboratories, Sysmex Corporation, Kobe, Hyogo 651-0073, Japan.
  • Respiratory Medicine, Kawasaki Medical School, Kurashiki, Okayama 701-0192, Japan.
  • Thoracic Surgery, Fukushima Medical University, Fukushima, Fukushima 960-1295, Japan.
  • Respiratory Medicine, Nagasaki Prefecture Shimabara Hospital, Shimabara, Nagasaki 855-0861, Japan.
  • Respiratory Medicine, The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Nagasaki 852-8511, Japan.
  • Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Nagasaki 852-8501, Japan.

Zitieren

APA

Sakaeda, K., Kurose, K., Matsumura, Y., Muto, S., Fukuda, M., Sugasaki, N., Fukuda, M., Takemoto, S., Taniguchi, H., Masuda, T., Shimizu, K., Kataoka, Y., Irino, Y., Sakai, Y., Atarashi, Y., Yanagida, M., Hattori, N., Mukae, H., Nakata, M., …, & Oka, M. (2024). Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2024.100830

Vancouver

Sakaeda K, Kurose K, Matsumura Y, Muto S, Fukuda M, Sugasaki N, et al. Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer. Cancer Treatment and Research Communications. 2024. doi:10.1016/j.ctarc.2024.100830

BibTeX
@article{Sakaeda2024,
  author = {Sakaeda, Kanako and Kurose, Koji and Matsumura, Yuki and Muto, Satoshi and Fukuda, Minoru and Sugasaki, Nanae and Fukuda, Masaaki and Takemoto, Shinnosuke and Taniguchi, Hirokazu and Masuda, Takeshi and Shimizu, Katsuhiko and Kataoka, Yuki and Irino, Yasuhiro and Sakai, Yumiko and Atarashi, Yusuke and Yanagida, Masatoshi and Hattori, Noboru and Mukae, Hiroshi and Nakata, Masao and Kanda, Eiichiro and Oga, Toru and Suzuki, Hiroyuki and Oka, Mikio},
  title = {Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer},
  journal = {Cancer Treatment and Research Communications},
  year = {2024},
  doi = {10.1016/j.ctarc.2024.100830}
}
Kostenlos starten →